FRED HUTCHINSON CANCER CENTER

Stanford Medicine researchers have developed a revolutionary blood test that analyzes cell-free RNA molecules to detect cancers at various stages, including early-stage lung cancer with 73% accuracy.

The Lupus Research Alliance has launched its Targeted Research Program on Engineered Cell Therapies for Lupus (TRP-ECT), awarding grants to 11 researchers developing innovative cellular treatments.

Fred Hutch researchers have identified KEAP1 gene inactivation as a critical mechanism behind chemotherapy resistance in small cell lung cancer, offering new insights into why initially effective treatments fail.

Novel trial combining idecabtagene vicleucel with lenalidomide maintenance shows promise for multiple myeloma patients following autologous stem cell transplantation.

• CELESTIAL trial establishes cabozantinib as standard second and third-line treatment for HCC, demonstrating improved overall survival of 10.2 months vs 8.0 months with placebo. • COSMIC-312 trial shows mixed results with cabozantinib-atezolizumab combination, achieving PFS benefits but failing to meet OS endpoints in first-line HCC treatment. • New research initiatives explore innovative combinations including novel immune checkpoint inhibitors, radiation therapy, and emerging cellular therapies like GPC3-targeted CAR T-cells.

Experts project a 40% increase in cancer care demand amid growing oncologist shortages, emphasizing the critical need for streamlined collaboration between healthcare providers and payers.

A phase 2 study at Fred Hutchinson Cancer Center demonstrates that peri-transplant ruxolitinib combined with standard GVHD prophylaxis reduces acute GVHD incidence to 32%, compared to 71% with pre-transplant treatment.

Unrelated umbilical cord blood transplantation demonstrated a 74% two-year overall survival rate in patients with hematologic malignancies, with particularly strong outcomes in pediatric patients.

A systematic literature review presented at ASH 2024 demonstrates that clinical trials significantly underestimate the health-related quality of life burden in relapsed/refractory multiple myeloma patients compared to real-world settings.

A pooled analysis of SWOG trials reveals that reducing dexamethasone doses below 40-60mg weekly does not negatively impact survival outcomes in newly diagnosed multiple myeloma patients.